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Abstract
Introduction Adjustment of infliximab dosage for individuals
may be useful in improving therapeutic response in rheumatoid
arthritis (RA). Herein, we aimed to determine whether
measurement of infliximab serum concentration modifies the
therapeutic decision and improves the control of disease
activity.
Methods RA patients routinely treated with infliximab were
included in an observational open-label study. On visit 1 (V1),
according to the disease activity, a preliminary therapeutic
decision was selected among four therapeutic options and a
blood sample was collected to measure trough serum infliximab
concentration. The final therapeutic decision, based on both
disease activity and serum infliximab concentration assessed at
V1, was applied at the following infusion (V2). Clinical and
biological evaluations were performed at V3 and V4 and
compared with those at V1.
Results We included 24 patients. The final therapeutic decision
differed from the preliminary decision for 12 patients (50%). For
patients with increased infliximab dosage at V2, mean disease
activity score for 28 joints (DAS28) decreased by about 20% at
V3 or V4 as compared with V1 (P < 0.05). Decreased DAS28
was correlated with increased serum infliximab concentration (P
< 0.02).
Conclusions The measurement of infliximab trough
concentration modifies the therapeutic decision for RA patients
and helps improve control of disease activity. Therapeutic drug
monitoring of infliximab in RA may be useful for individual
dosage adjustment.
Introduction
Infliximab is a chimeric monoclonal antibody against tumor
necrosis factor-alpha (TNF-α) used in the treatment of rheuma-
toid arthritis (RA); its efficacy was demonstrated in a rand-
omized controlled trial [1]. The variable inter-individual
response is explained at least in part by individual pharmacok-
inetics [2]. Clinical response in RA is indeed influenced by inf-
liximab serum concentration [2-6], and we have recently
shown that this concentration predicts long-term disease con-
trol in daily practice [7]. Adjustment of infliximab dosage for
individuals may be useful in improving therapeutic response
[8,9]. Hence, patients with persistent active disease and low
infliximab concentrations could benefit from an increase in inf-
liximab dosage, whereas those with poor disease control and
high infliximab concentrations should switch to another biop-
harmaceutical. In contrast, patients with optimal disease con-
trol and high infliximab concentrations might benefit from a
ATI: antibody toward infliximab; DAS28: disease activity score for 28 joints; ELISA: enzyme-linked immunosorbent assay; RA: rheumatoid arthritis; 
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controlled reduction in infliximab dose or an increase of dosing
intervals to decrease the risk of dose-related side effects.
We aimed to determine whether the measurement of serum
infliximab concentration modifies the therapeutic strategy and
improves the control of disease activity in RA. The secondary
objective was to study whether this improvement in control of
disease activity is related to changes in infliximab concentra-
tion.
Materials and methods
Patients
All RA patients visiting our rheumatology department from May
to August 2007 to receive their routine infliximab infusion,
according to recommendations from the French Society for
Rheumatology for patients receiving anti-TNF biopharmaceuti-
cals [10], were followed up during four visits (V1 to V4).
According to the rules applied in our setting, patients were
asked to complete a weekly questionnaire recording pain, joint
stiffness, and disease activity on visual analog scales to esti-
mate overall disease activity since the last infusion. In this
observational study, eligible patients had received at least four
infusions of infliximab, had an infliximab dose (in milligrams per
kilograms) and dosing interval (± 4 days) similar to those of the
previous infusion, had no change in use of disease-modifying
anti-rheumatic drugs since the previous infusion, and had no
pregnancy or surgery scheduled within the following three
infusions. The study design is summarized in Figure 1. The
patients gave their informed consent to participate in the
study, and the study protocol was in compliance with the Dec-
laration of Helsinki. This study was approved by our local insti-
tutional review board.
Serum concentrations of infliximab and antibody toward 
infliximab
A blood sample was drawn just before each infusion from V1
to V4. Serum infliximab concentrations were measured by
enzyme-linked immunosorbent assay (ELISA) as previously
described [11]. The limit of detection of this technique is
0.014 μg/mL. The lower limit of quantitation and upper limit of
quantitation are 0.04 and 4.5 μg/mL, respectively. Serum con-
centrations of antibody toward infliximab (ATI) were measured
by double-antigen ELISA with capture by infliximab-coated
microplates and detection by peroxydase-coupled infliximab.
The ELISA was standardized by use of a mouse monoclonal
antibody to all subclasses of human IgG. The limit of detection
was 0.20 μg/mL. The technique was tested on 195 serum
samples from healthy blood donors (37%), patients with
autoimmune diseases (59.5%), and patients with hypergam-
maglobulinemia (3.5%) and did not lead to false-positive
results, even in the presence of rheumatoid factor. Because of
the interference with circulating infliximab, results were con-
clusive if the infliximab concentration in the sample was less
than 1.7 μg/mL.
Preliminary therapeutic decision (before knowing 
infliximab concentration)
The preliminary therapeutic decision at V1 was based on clin-
ical and conventional laboratory marker testing. Control of dis-
ease activity was categorized as 'optimal', 'acceptable', or
'inadequate' by a combination of disease activity score for 28
joints (DAS28) and physician global assessment. Taking into
account the control of disease activity, the physician selected
a preliminary therapeutic decision from among four options:
(a) decrease infliximab dosage, (b) maintain the same inflixi-
mab dosage and possibly add another therapeutic intervention
(that is, intra-articular corticosteroid injection, physical treat-
ment, or analgesic pharmaceuticals), (c) increase infliximab
dosage, or (d) discontinue infliximab and switch to another
treatment. An increase in infliximab dosage was not possible if
the V1 dosage was considered maximal (that is, a dose of at
least 7.5 mg/kg or an interval of not more than 4 weeks).
Figure 1
Study design Study design. Each visit corresponds to infliximab infusion and included clinical assessment, a blood sample for measurement of infliximab, and test-
ing for antibody against infliximab. The final therapeutic decision took into account infliximab concentration measured at visit 1. RA, rheumatoid arthri-
tis.Available online http://arthritis-research.com/content/11/6/R178
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Final therapeutic decision
The final therapeutic decision applied at V2 (Figure 1) took
into account both the assessment of disease activity and the
trough serum infliximab concentration measured at V1 (Table
1). According to available published data [2,3,12,13], a target
infliximab serum concentration of 5 μg/mL was selected.
Trough infliximab concentration was classified as low (<2.0
μg/mL), medium (≥2.0 and <8 μg/mL), or high (≥8 μg/mL).
Statistical analysis
Clinical and biological markers of disease activity, DAS28, and
trough serum infliximab concentration at V1 were compared
with those at V3 and V4. Statistical differences were analyzed
by the Wilcoxon non-parametric test for continuous variables.
The relation between change in infliximab serum concentration
and change in DAS28 from V1 to V4 was analyzed by the
Spearman non-parametric correlation test. Statistical analysis
involved Statview version 5 (SAS Institute Inc., Cary, NC,
USA). A two-tailed P value of less than 0.05 was considered
statistically significant. Results are presented as median
[range] unless otherwise stated.
Results
Characteristics of patients
A total of 24 patients (8 men) were included. The median age
was 61 years [34 to 78], and the disease duration was 10
years [5 to 58]. The median duration of infliximab treatment
was 56 months [3 to 76], and the number of previous inflixi-
mab infusions was 31 [4 to 39]. Before receiving infliximab, 2
patients (9%) had received one of the two other anti-TNF-α
biopharmaceuticals available at that time. Sixteen patients
were receiving prednisone (dose/day = 5 mg [0.5 to 10.0]),
and 20 patients were receiving methotrexate (dose = 10 mg/
week [5 to 17.5]). The median interval between infliximab infu-
sions was 8 weeks [6 to 9], and the dose of infliximab infusion
was 3.75 mg/kg [2.80 to 7.30]. The median infliximab concen-
tration was 3.00 μg/mL [0.01 to 7.80]. No patient had a high
trough infliximab concentration, 17 patients (71%) had
medium trough concentrations, and 7 (29%) had low trough
concentrations. The median erythrocyte sedimentation rate
was 14 mm/hour [5 to 49], the level of C-reactive protein was
5.0 mg/L [0.6 to 22.0], and DAS28 was 2.65 [1.48 to 6.16].
At V1, 12 patients (50%) showed optimal control of disease
activity, 5 (21%) acceptable control, and 7 (29%) inadequate
control. Only one patient was positive for ATI at V1 (2.18 μg/
mL) with a concomitant infliximab concentration that was
undetectable (0.01 μg/mL). This patient had been receiving
infliximab for 9 months. Her infliximab dosage was increased
during the study, but she eventually discontinued the treat-
ment after V4.
Difference between preliminary and final therapeutic 
decision
The final therapeutic decision, taking into account serum inflix-
imab concentration, differed from the preliminary therapeutic
decision for 12 patients (50%) (Additional data file 1). For 7
patients, the infliximab dosage was increased for the final ther-
apeutic decision as compared with 3 patients for whom the
dosage was increased at the preliminary therapeutic decision.
Of the 7 patients, 6 were considered to have an inadequate
control of disease activity (2 with medium and 4 with low inflix-
imab concentration) and 1 was considered to have acceptable
control (with medium infliximab concentration).
Evolution of clinical and biological markers of disease 
activity
Changes in DAS28 over time are presented in Figure 2.
DAS28 significantly improved from V1 to V3 (P < 0.05) for
patients with an increase in infliximab dosage. The mean
improvement in DAS28 for patients of this group was about
20%. The improvement as compared with V1 was maintained
at V4 (P < 0.05).
Relation between change in serum infliximab 
concentration and change in disease activity
As shown in Figure 3, changes in DAS28 and infliximab con-
centration between V1 and V4 were inversely related (P <
0.02).
Table 1
Final therapeutic decision at visit 2 based on disease activity control and serum trough infliximab concentration
Control of disease activity
Optimal Acceptable Inadequate
High: C (μg/mL) ≥8.0 Decrease infliximab 
dosage
Maintain same infliximab 
dosage
Switch to another 
biopharmaceutical
Infliximab trough 
concentration
Medium: 2.0 ≤ C (μg/mL) 
<8.0
Maintain same infliximab 
dosage
Consider increasing infliximab dosagea
Increase infliximab dosage Low: C (μg/mL) <2.0 Maintain same infliximab 
dosage
Infliximab dosage could not be increased if the current dosage was considered maximal (that is, at least 7.5 mg/kg or interval of not more than 4 
weeks). aIf the physician kept the same infliximab dosage, another therapeutic intervention could be added (that is, intra-articular corticosteroid 
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Discussion
To our knowledge, this is the first study to highlight the useful-
ness of pharmacokinetic monitoring of infliximab concentration
to control disease activity in RA. Indeed, the measurement of
trough infliximab concentration modified the therapeutic deci-
sion for half of our patients and led to improved control of dis-
ease activity for patients for whom infliximab dosage was
increased. Our results confirm those of a clinical observational
study that did not monitor infliximab concentrations [8]. The
strength of our approach lies in a strategy that took into
account both disease activity and serum infliximab concentra-
tion.
The second important finding is the relation between increase
in serum infliximab concentration and clinical improvement, as
measured by the DAS28. Because concomitant medications
remained unchanged during the study for patients whose inf-
liximab dosage had been increased, the improvement in
DAS28 should have resulted from the increase in infliximab
concentration. Our results also confirm the inter-individual var-
iability of infliximab pharmacokinetics. Despite a median inflixi-
mab dose (3.75 mg/kg [2.80 to 7.30]) above that
recommended in patients with RA, 7 patients (29%) had low
trough concentrations.
Clinicians can face two situations with RA patients receiving
infliximab. The first corresponds to patients with optimal dis-
ease control, for whom the physician could consider reducing
infliximab dosage. However, a decrease in infliximab dosage
without infliximab concentration monitoring may lead to under-
exposure, a situation that can predict insufficient control of dis-
ease activity and increased risk of positivity for ATI [4,14]. For
the preliminary therapeutic decision, infliximab dosage reduc-
tion was planned for 6 patients; however, because these
patients were all considered satisfactorily exposed or underex-
posed, they continued the same regimen for the final therapeu-
tic decision. The second situation corresponds to patients
with disease control the physician considers acceptable or
inadequate. In this situation, the physician could consider
increasing the infliximab dosage to improve the control of dis-
ease activity. However, concerns arise in the prolonged use of
TNF-α antagonists, especially at high doses [15]. Therefore,
the measurement of serum infliximab concentration in this sit-
uation could be useful to avoid an unnecessary increase in
dosage in patients with concurrent high infliximab concentra-
tion and hence a risk of dose-dependent side effects. Monitor-
ing of infliximab concentrations in this situation would lead the
clinician to increase the dosage only if the patient does not
have a high infliximab concentration. Therapeutic drug moni-
toring of infliximab could result in a lowering of dosage in
patients having higher exposure than needed, in an increasing
of dosage in others, or in a discontinuation of infliximab in non-
responders with high exposure. As a whole, such a strategy
should improve the cost-effectiveness of infliximab in RA.
Our method to determine infliximab serum concentration
detects the active form of infliximab (that is, the species that
can bind to TNF-α), not infliximab molecules that are already
bound to TNF-α or ATI. The choice of measuring the active
form allows investigators to analyze the concentration-effect
relationship.
Immunogenicity induced by anti-TNF-α biopharmaceuticals
has been associated with low concentrations and poor clinical
outcomes [16]. Our technique for ATI detection was limited by
the presence of circulating infliximab. The problem is well
known and is encountered whatever the method used [17].
Also, ATI may have underestimated the infliximab determina-
tion by neutralizing both infliximab paratopes. However, such
undetectable infliximab molecules are inactive and cannot be
taken into account for pharmacokinetic-pharmacodynamic
analysis. Positivity for ATI influences the pharmacokinetics of
Figure 2
Relative change in mean disease activity score for 28 joints (DAS28)  over time according to final therapeutic decision (Table 1) Relative change in mean disease activity score for 28 joints (DAS28) 
over time according to final therapeutic decision (Table 1). *P < 0.05.
Figure 3
Relation between change in serum infliximab concentration and change  in disease activity score for 28 joints (DAS28) from visit 1 to visit 4 Relation between change in serum infliximab concentration and change 
in disease activity score for 28 joints (DAS28) from visit 1 to visit 4. 
Because of missing data, four patients are not represented.Available online http://arthritis-research.com/content/11/6/R178
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infliximab in ankylosing spondylitis [18] and inflammatory
bowel disease [19], but the determining factor in the concen-
tration-effect relation of infliximab is infliximab itself.
Only one patient was positive for ATI, and this can be
explained by the duration of infliximab treatment, 56 months [3
to 76]. Indeed, patients positive for ATI probably had already
switched to another treatment because of clinical signs of
immunization or secondary failure of treatment. ATI false-neg-
ative results may have occurred for sera with detectable inflix-
imab concentrations.
Our study has several limitations. Because it is an open-label
observational study, patients may have been influenced by the
therapeutic decision, especially those who were notified of an
increase in infliximab dosage. Therefore, our results need to be
confirmed by a randomized controlled study comparing thera-
peutic drug monitoring of infliximab with usual care. Also, our
approach, based on a single clinical assessment, can be
applied only for patients considered to have stable disease
activity and not those with acute flare, whose condition
requires a rapid therapeutic intervention. Because patients
with acute flare were not considered in our study, we cannot
extend our strategy to such patients. Because RA activity var-
ies with time, we used a weekly diary to estimate global dis-
ease activity between two consecutive infusions to limit this
factor. Another limitation of our study is that our population of
RA patients had been treated for a long time with infliximab.
Whether a dosage adjustment during the early initiation of
treatment could be of benefit in terms of response is a chal-
lenging question. Since the concentration-effect relationship
of infliximab is poorly known, therapeutic drug monitoring will
be more difficult to test at treatment initiation. For that reason,
our results apply only to RA patients with a relatively long
period of treatment, not to patients at their initiation.
Conclusions
The measurement of serum trough infliximab concentration
modifies the therapeutic decision for RA patients and leads to
improved control of disease activity. Thus, therapeutic drug
monitoring of infliximab may improve the control of disease
activity in RA.
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